Lactobacillus crispatus L1: high cell density cultivation and exopolysaccharide structure characterization to highlight potentially beneficial effects against vaginal pathogens

BMC Microbiology

Chiara Schiraldi¹  Mario De Rosa¹  Vincenza De Gregorio³  Vivien Valli¹  Cristina De Castro²  Donatella Cimini¹  Antonio Molinaro²  Giovanna Donnarumma³ 

[1] Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, Second University of Naples, via De Crecchio n°7, Naples 80138, Italy;Department of Chemical Sciences, University of Naples Federico II, via Cinthia 4, Naples 80126, Italy;Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, Second University of Naples, via De Crecchio n°7, Naples 80138, Italy

关键词: Simulated digestion;    High cell densities cultivation;    L. crispatus L1;   

Others  :  1140995
DOI  :  10.1186/1471-2180-14-137

 received in 2014-02-19, accepted in 2014-05-21,  发布年份 2014

【 摘 要 】

Background

Vaginal lactic acid bacteria defend the host against pathogens through a combination of competitive exclusion, competition for nutrients, production of antimicrobial substances and through the activation of the immune system. A new human isolate named Lactobacillus crispatus L1 was characterized in this work, and a preliminary evaluation of its probiotic potential is described together with a process to obtain a high productivity of viable biomass.

Results

In a simulated digestion process 1.8⋅10¹⁰ cells∙ml⁻¹ survived the gastric environment with 80% viability, without being affected by small intestine juices. Experiments on six different C sources were performed to analyze growth and organic acids production and, glucose, provided the best performances. A microfiltration strategy was exploited to improve the cellular yield in 2 L-fermentation processes, reaching 27 g · l⁻¹ of dry biomass. Moreover, L. crispatus L1 demonstrated a greater stability to high concentrations of lactic acid, compared to other lactobacilli. The specific L. crispatus L1 exopolysaccharide was purified from the fermentation broth and characterized by NMR showing structural features and similarity to exopolysaccharides produced by pathogenic strains. Live L. crispatus L1 cells strongly reduced adhesion of a yeast pathogenic strain, Candida albicans in particular, in adherence assays. Interestingly a higher expression of the human defensin HBD-2 was also observed in vaginal cells treated with the purified exopolysaccharide, indicating a possible correlation with C. albicans growth inhibition.

Conclusions

The paper describes the evaluation of L. crispatus L1 as potential vaginal probiotic and the fermentation processes to obtain high concentrations of viable cells.

【 授权许可】

   
2014 Donnarumma et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Schiffrin EJ, Blum S: Interactions between the microbiota and the intestinal mucosa. Eur J Clin Nutr 2002, 56(Suppl 3):S60-S64.
• [2]Beck CNH: Beneficial effects of administration of Lactobacillus acidophilus in diarrheal and other intestinal disorders. Am J Gastroenterol 1961, 35:522-530.
• [3]Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT: Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis. Ann Intern Med 1992, 116:353-357.
• [4]Kaewnopparat S, Dangmanee N, Kaewnopparat N, Srichana T, Chulasiri M, Settharaksa S: In vitro probiotic properties of Lactobacillus fermentum SK5 isolated from vagina of a healthy woman. Anaerobe 2013, 22:6-13.
• [5]Mastromarino P, Vitali B, Mosca L: Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol 2013, 36:229-238.
• [6]Reid GZCGG: Urogenital Lactobacilli Probiotics, Reliability, and Regulatory Issues. J Dairy Sci 2001, 84:E164-E169.
• [7]Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T: A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991, 88:90-97.
• [8]Cadieux PA, Burton J, Devillard E, Reid G: Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J Physiol Pharmacol 2009, 60(Suppl 6):13-18.
• [9]Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G: Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect 2006, 8:2772-2776.
• [10]Parma M, Dindelli M, Caputo L, Redaelli A, Quaranta L, Candiani M: The role of vaginal Lactobacillus Rhamnosus (Normogin(R)) in preventing Bacterial Vaginosis in women with history of recurrences, undergoing surgical menopause: a prospective pilot study. Eur Rev Med Pharmacol Sci 2013, 17:1399-1403.
• [11]Boskey ER, Telsch KM, Whaley KJ, Moench TR, Cone RA: Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun 1999, 67:5170-5175.
• [12]Vallor AC, Antonio MA, Hawes SE, Hillier SL: Factors associated with acquisition of, or persistent colonization by, vaginal lactobacilli: role of hydrogen peroxide production. J Infect Dis 2001, 184:1431-1436.
• [13]Homayouni A, Bastani P, Ziyadi S, Mohammad-Alizadeh-Charandabi S, Ghalibaf M, Mortazavian AM, Mehrabany EV: Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis 2014, 18:79-86.
• [14]Bruce AW, Reid G: Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can J Microbiol 1988, 34:339-343.
• [15]Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM, Holmes KK: Prevalence of hydrogen peroxide-producing Lactobacillus species in normal women and women with bacterial vaginosis. J Clin Microbiol 1989, 27:251-256.
• [16]Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning B: Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001, 30:49-52.
• [17]Morelli L, Zonenenschain D, Del PM, Cognein P: Utilization of the intestinal tract as a delivery system for urogenital probiotics. J Clin Gastroenterol 2004, 38:S107-S110.
• [18]Walter J: Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. Appl Environ Microbiol 2008, 74:4985-4996.
• [19]Ma B, Forney LJ, Ravel J: Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol 2012, 66:371-389.
• [20]Kirtzalidou E, Pramateftaki P, Kotsou M, Kyriacou A: Screening for lactobacilli with probiotic properties in the infant gut microbiota. Anaerobe 2011, 17:440-443.
• [21]Pascual LM, Daniele MB, Ruiz F, Giordano W, Pajaro C, Barberis L: Lactobacillus rhamnosus L60, a potential probiotic isolated from the human vagina. J Gen Appl Microbiol 2008, 54:141-148.
• [22]Vielfort K, Sjolinder H, Roos S, Jonsson H, Aro H: Adherence of clinically isolated lactobacilli to human cervical cells in competition with Neisseria gonorrhoeae. Microbes Infect 2008, 10:1325-1334.
• [23]Anokhina IV, Kravtsov EG, Protsenko AV, Yashina NV, Yermolaev AV, Chesnokova VL, Dalin MV: Bactericidal activity of culture fluid components of Lactobacillus fermentum strain 90 TS-4 (21) clone 3, and their capacity to modulate adhesion of Candida albicans yeast-like fungi to vaginal epithelial cells. Bull Exp Biol Med 2007, 143:359-362.
• [24]Selsted ME, Ouellette AJ: Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005, 6:551-557.
• [25]Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
• [26]Sandal I, Inzana TJ, Molinaro A, De CC, Shao JQ, Apicella MA, Cox AD, St MF, Berg G: Identification, structure, and characterization of an exopolysaccharide produced by Histophilus somni during biofilm formation. BMC Microbiol 2011, 11:186. BioMed Central Full Text
• [27]Harriott MM, Noverr MC: Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol 2011, 19:557-563.
• [28]Vasquez A, Jakobsson T, Ahrne S, Forsum U, Molin G: Vaginal lactobacillus flora of healthy Swedish women. J Clin Microbiol 2002, 40:2746-2749.
• [29]Balashov SV, Mordechai E, Adelson ME, Sobel JD, Gygax SE: Multiplex quantitative polymerase chain reaction assay for the identification and quantitation of major vaginal lactobacilli. Diagn Microbiol Infect Dis 2014, 78:321-327.
• [30]Borgdorff H, Tsivtsivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, Schuren FH, van de Wijgert JH: Lactobacillus-dominated cervicovaginal microbiota associated with reduced HIV/STI prevalence and genital HIV viral load in African women. ISME J 2014, 2014:2014.
• [31]Martin R, Soberon N, Vazquez F, Suarez JE: [Vaginal microbiota: composition, protective role, associated pathologies, and therapeutic perspectives]. Enferm Infecc Microbiol Clin 2008, 26:160-167.
• [32]Burgos-Rubio CN, Okos MR, Wankat PC: Kinetic study of the conversion of different substrates to lactic acid using Lactobacillus bulgaricus. Biotechnol Prog 2000, 16:305-314.
• [33]Anukam K, Osazuwa E, Ahonkhai I, Ngwu M, Osemene G, Bruce AW, Reid G: Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006, 8:1450-1454.
• [34]Schiraldi C, Adduci V, Valli V, Maresca C, Giuliano M, Lamberti M, Carteni M, De RM: High cell density cultivation of probiotics and lactic acid production. Biotechnol Bioeng 2003, 82:213-222.
• [35]Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D, Motherway MO, Shanahan F, Nally K, Dougan G, van Sinderen D: Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A 2012, 109:2108-2113.
• [36]Denou E, Pridmore RD, Berger B, Panoff JM, Arigoni F, Brussow H: Identification of genes associated with the long-gut-persistence phenotype of the probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and transcriptome analysis. J Bacteriol 2008, 190:3161-3168.
• [37]Ifrim DC, Joosten LA, Kullberg BJ, Jacobs L, Jansen T, Williams DL, Gow NA, van der Meer JW, Netea MG, Quintin J: Candida albicans primes TLR cytokine responses through a Dectin-1/Raf-1-mediated pathway. J Immunol 2013, 190:4129-4135.
• [38]Kimmel SA, Roberts RF: Development of a growth medium suitable for exopolysaccharide production by Lactobacillus delbrueckii ssp. bulgaricus RR. Int J Food Microbiol 1998, 40:87-92.
• [39]Juarez Tomas MS, Saralegui Duhart CI, De Gregorio PR, Vera PE, Nader-Macias ME: Urogenital pathogen inhibition and compatibility between vaginal Lactobacillus strains to be considered as probiotic candidates. Eur J Obstet Gynecol Reprod Biol 2011, 159:399-406.
• [40]Neefs JM, Van de Peer Y, De RP, Chapelle S, De WR: Compilation of small ribosomal subunit RNA structures. Nucleic Acids Res 1993, 21:3025-3049.
• [41]Tomas MS, Claudia OM, Ocana V, Elena Nader-Macias M: Production of antimicrobial substances by lactic acid bacteria I: determination of hydrogen peroxide. Methods Mol Biol 2004, 268:337-346.
• [42]Kos BSJGJMS: Effect of Protectors on the Viability of Lactobacillus acidophilus M92 in Simulated Gastrointestinal Conditions. Food technol Biotechnol 2000, 38:121-127.
• [43]Loweus FA: Improvement in anthrone method for the determination of carbohydrates. Anal Chem 1952, 24:19.
• [44]De Castro C, Kenyon JJ, Cunneen MM, Molinaro A, Holst O, Skurnik M, Reeves PR: The O-specific polysaccharide structure and gene cluster of serotype O:12 of the Yersinia pseudotuberculosis complex, and the identification of a novel L-quinovose biosynthesis gene. Glycobiology 2013, 23:346-353.
• [45]De Castro C, Parrilli M, Holst O, Molinaro A: Microbe-associated molecular patterns in innate immunity: Extraction and chemical analysis of gram-negative bacterial lipopolysaccharides. Methods Enzymol 2010, 480:89-115.
• [46]Maggi L, Mastromarino P, Macchia S, Brigidi P, Pirovano F, Matteuzzi D, Conte U: Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration. Eur J Pharm Biopharm 2000, 50:389-395.
• [47]Osset J, Bartolome RM, Garcia E, Andreu A: Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis 2001, 183:485-491.